Explore 3 Stock Ideas & Industry Insights Download Free Report

Lunai Bioworks Inc.

Company price
None USD 0.00(0%)
Last update at 2026-11-19T21:46:02.571190Z
Market Cap
9.93M

Momentum Score

…

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.21
Low
15.36
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Publicly listed on Nasdaq, Lunai Bioworks Inc. is a life sciences company with limited publicly available operational detail; investors should consult company filings and disclosures for specifics. Long-term growth may depend on progress in its research and development, successful regulatory clearances or partnerships, and broader adoption in the biotechnology sector, which could support future revenue expansion and market positioning.
Primary investment risks include limited disclosure and transparency, early-stage or unproven technologies, significant regulatory and financing uncertainty, and likely low liquidity and high volatility in the stock.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.16
Dividend Yield
-
Revenue TTM
0.02M
Revenue Per Share
0.01
Gross Profit TTM
0.02M
Debt / Equity
-0.48
ROE
-325.46%
Net Debt
10.08M
ROCE
847.21%
Diluted EPS TTM
-60.67

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -178.01M -88.43M -39.68M -113.43M -26.85M
Net income -178.01M -88.43M -39.68M -113.43M -26.72M
Selling general administrative 17.88M 24.56M 15.32M 14.33M -
Gross profit -0.13M 0.00M 0.00M - -0.39M
Reconciled depreciation 0.13M 0.12M 0.11M 0.12M -
Ebit -177.28M -85.99M -38.98M -113.06M -26.47M
Ebitda -177.15M -85.87M -38.86M -112.94M -26.08M
Depreciation and amortization 0.13M 0.12M 0.11M 0.12M 0.39M
Operating income -18.55M -81.64M -38.56M -116.08M -23.40M
Other operating expenses 18.55M 81.64M 38.56M 116.08M 23.40M
Interest expense 0.73M 2.43M 0.71M 0.37M 0.38M
Tax provision - - 0.00M 0.00M -
Interest income 0.12M - - 0.12M -
Net interest income -0.61M -2.43M -0.71M -0.25M -
Income tax expense - - - 0.00M -0.13M
Total revenue 0.00M 0.00M 0.00M 0.00M -
Total operating expenses 18.42M 81.64M 38.56M 116.08M 23.01M
Cost of revenue 0.13M - - - 0.39M
Total other income expense net -159.46M -6.79M -1.13M 2.65M -3.45M
Net income from continuing ops -178.01M -88.43M -39.68M -113.43M -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 8.23M 163.13M 58.30M 84.63M 189.61M
Intangible assets 0.17M 0.03M 42.65M 61.62M 154.89M
Other current assets 0.57M 0.67M 0.69M 0.39M 0.23M
Total liab 29.58M 31.15M 11.80M 12.01M 14.94M
Total stockholder equity -21.35M 131.98M 46.50M 72.62M 174.66M
Other current liab 6.85M 17.92M 0.91M 3.60M 1.21M
Common stock 0.02M 0.02M 0.01M 0.01M 0.01M
Capital stock 0.02M 0.02M 0.01M 0.01M -
Retained earnings -510.46M -332.46M -244.03M -204.35M -90.91M
Good will 5.96M 159.33M 11.64M 11.64M 11.64M
Cash 0.09M 0.22M 1.87M 9.17M 20.66M
Total current liabilities 29.16M 30.31M 11.02M 6.45M 1.89M
Net debt 10.08M 3.57M 3.72M -2.16M -13.29M
Short term debt 9.75M 2.94M 4.82M 1.45M 0.35M
Short long term debt 9.44M 2.45M 4.62M 1.20M -
Short long term debt total 10.17M 3.79M 5.59M 7.02M 7.37M
Other stockholder equity 478.28M 464.59M 290.55M 276.99M 265.58M
Total current assets 1.05M 2.00M 2.57M 9.57M 20.90M
Short term investments 0.39M 0.00M - - -
Net receivables - 1.11M - - 0.00M
Long term debt - - - 4.58M -
Accounts payable 12.56M 9.45M 5.30M 1.40M 0.32M
Accumulated other comprehensive income 10.81M -0.17M -0.03M -0.03M -0.01M
Non currrent assets other - 0.02M 0.02M 0.07M 0.02M
Non current assets total 7.18M 161.13M 55.74M 75.07M 168.71M
Capital lease obligations 0.74M 1.34M 0.97M 1.24M -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.50M -1.26M -0.03M -0.01M -
Total cashflows from investing activities -0.50M -1.26M -0.03M -0.01M -0.05M
Net borrowings 6.98M 8.05M 0.00M -0.56M -
Total cash from financing activities 8.38M 10.52M 4.52M 4.25M 32.60M
Net income -178.01M -88.43M -39.68M -113.43M -26.72M
Change in cash -0.13M -1.65M -7.30M -11.49M 11.97M
Begin period cash flow 0.22M 1.87M 9.17M 20.66M 8.70M
End period cash flow 0.09M 0.22M 1.87M 9.17M 20.66M
Total cash from operating activities -7.87M -10.97M -11.77M -15.73M -20.61M
Issuance of capital stock 2.38M 3.00M 4.01M 4.68M -
Depreciation 0.13M 0.12M 0.11M 0.12M 0.39M
Change to account receivables 1.15M -1.11M 0.00M 0.00M 0.00M
Other cashflows from financing activities -0.97M -0.53M 0.50M 0.13M 1.22M
Capital expenditures 0.00M 0.07M 0.03M 0.01M 0.05M
Change in working capital 5.86M 8.81M 4.31M 1.42M 0.93M
Stock based compensation 3.31M 4.67M 3.54M 5.49M -
Other non cash items 160.83M 63.85M 19.96M 90.67M 4.79M
Free cash flow -7.87M -11.04M -11.80M -15.74M -20.66M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-0.54
1.36%
38.90 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-
-%
520.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
2.34
0.25%
923.34 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Lunai Bioworks Inc.

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.

2080 Century Park East, Los Angeles, CA, United States, 90067

305 918 1980

29

Name Title Year Born
Mr. David H. Weinstein CEO & Director 1961
Mr. Nathen Fuentes CPA Chief Financial Officer 1983

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…